ArticleEndocrine2026
Type 2 diabetes in BRICS countries from 1990 to 2023: burden, trends and complementary Mendelian randomization evidence.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe burden of type 2 diabetes (T2D) is increasing across BRICS countries, but cross-national comparative evidence on recent trends and drivers is limited.
methodsUsing Global Burden of Disease (GBD) 2023 data, we analyzed T2D-related deaths, years of life lost (YLLs), years lived with disability (YLDs) and disability-adjusted life years (DALYs) from 1990 to 2023 in Brazil, Russia, India, China and South Africa. Age-standardized rates, estimated annual percentage changes, joinpoint trends, decomposition of changes in absolute burden, and Bayesian age-period-cohort projections were evaluated. Attributable burden was assessed using the GBD comparative risk assessment framework. As a secondary analysis, two-sample Mendelian randomization (MR) was performed for selected exposures using external GWAS datasets of predominantly European ancestry, without using the MR estimates to explain between-country differences or to validate the GBD attribution.
resultsIn 2023, India had the largest absolute burden of type 2 diabetes, whereas South Africa had the highest age-standardized DALY and mortality rates. China ranked second in absolute burden but lowest in age-standardized rates. From 1990 to 2023, age-standardized DALY rates increased in all five countries, with the steepest increases in India and the Russian Federation. Epidemiological change drove burden increases in India and Russia, population ageing in China, and population growth in Brazil and South Africa. High fasting plasma glucose and high BMI accounted for the largest attributable DALY fractions. In complementary MR analyses, adiposity, several glycemic traits, smoking initiation, and television viewing time showed positive primary-analysis associations with T2D, although these provide etiological context rather than BRICS-specific causal estimates.
conclusionsT2D burden in BRICS countries is high, heterogeneous, and still increasing, highlighting the need for country-specific prevention and care strategies.
Indexed as
Identifiers
42573636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.